Testing a new shigella vaccine in healthy people
Part of Digestive system, Infections clinical trials.
This study tests a new vaccine designed to protect against shigella, a bacteria that causes severe diarrhea. It is being tested in healthy adults, children, and infants to see if it is safe and how well it boosts the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18–45, children aged 2–5, or infants aged 6–11 months can join.
- Must be in good health, with no major illnesses or chronic conditions.
- No history of shigella infection or recent close contact with someone who has it.
- No other vaccines within 4 weeks before or after the study doses.
- No use of steroids or immunosuppressive drugs in the past 6 months.
- Must agree to use effective birth control if female and of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new Shigella vaccine in healthy adults to see if it is safe and creates a good immune response. It is a first-in-human study, meaning this is the first time the vaccine is given to people.
This Phase 1 study tests a Shigella (gut infection) vaccine and additives to see how safe they are in healthy adults. If you qualify, you may help researchers understand whether the vaccine triggers any unwanted immune or stomach side effects.
This trial tests an oral vaccine designed to protect against two common causes of severe diarrhea: shigella and ETEC bacteria. Healthy adults aged 18 to 50 will receive the vaccine and later be exposed to the bacteria to see if it works.
This trial checks how long the protection from the Shigella vaccine lasts in children who got the vaccine as babies. You child will have already been in a previous study, and we will simply follow up with a blood test to measure their immunity over time.
This Phase 1 study gives a carefully measured dose of Shigella sonnei to healthy adults to learn about the infection’s safety and how the body responds. It may help researchers build safer future tests or treatments, but it requires a hospital stay and many follow-up visits.
This study tests how well a recommended treatment works for children aged 6 months to 5 years who have diarrhea caused by Shigella bacteria. It aims to find the best way to help children recover faster.
Hear when a new Shigella Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.